trial

Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia Patients

NCTId NCT04572685
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 36 (actual)
Sponsored by Luye Pharma Group Ltd.
Primary completion 2020-06-26
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
36 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2020-01-22
Primary completion
2020-06-26
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Paliperidone

Sponsors

Luye Pharma Group Ltd.Lead Sponsor
Alliance for Clinical Trials in OncologyCollaborator
Evolution Research GroupCollaborator

Sites

1 total
Berlin, United States

Facts & assertions

4 sourced
Enrollment
36
Phase
PHASE1
Primary Completion Date
2020-06-26
Status
COMPLETED
relationships
The graph out of here
drug
Paliperidone
drug
lead_sponsor
Luye Pharma Group Ltd.
company
collaborator
Alliance for Clinical Trials in Oncology
company
Evolution Research Group
company
indication
Schizophrenia Patients
indication